Global Inactivated Vaccine Market
Global Inactivated Vaccine Market

Inactivated Vaccine Comprehensive Study by Type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), Application (Hospital, Medical Center) Players and Region - Global Market Outlook to 2024

Inactivated Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2019 Edition 205 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio and MMR) , by application (Hospital and Medical Center) and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Inactivated Vaccine market throughout the predicted period.

The competition is expected to become even more intense in the coming years with the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Inactivated Vaccine market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • Astellas Pharma (Japan)
  • CSL Limited (Australia)
  • Emergent BioSolutions (United States)
  • GlaxoSmithKline (United Kingdom)
  • Johnson & Johnson (United States)
  • MedImmune (United States)
  • Merck & Co (United States)
  • Pfizer (United States)
  • Sanofi Pasteur (France)
  • Serum Institute of India Pvt (India)


Market Overview:
Astellas Pharma Inc. announced acquisition of Potenza Therapeutics and and the company has also completed the acquisition of Mitobridge, Inc. and after that Mitobridge has become a wholly owned subsidiary of Astellas as of January 23, 2018

Market Trend
Expansion of customised vaccines and Implementation of Artificial Intelligence (AI) and Big Data Analytics to improve surveillance capacity
Restraints
  • Imbalance in the curing of disease
  • Safety and efficacy related issues

Opportunities
Substantial investments made in the field of research and development of vaccines and technologies is improving the market growth

Key highlights of the Global Inactivated Vaccine market Study:
• CAGR of the market during the forecast period 2018-2024
• Detailed information on factors that will accelerate the growth of the Inactivated Vaccine market for the next five years.
• Forecast of the Global Inactivated Vaccine market size and its contribution to the parent market by type, application and by country.
• Insights on upcoming trends and changes in consumer behaviour
• Uncovering market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Inactivated Vaccine Players

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Inactivated Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Inactivated Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Inactivated Vaccine providers, laboratories, Channel partners, Industry association, Downstream vendors, Government and investment communities, Research organisation and associations and End user.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • By End User
  • Pediatrics
  • Adults
  • By Disease Indication
  • Pneumococcal
  • Influenza
  • HPV
  • Hepatitis
  • Rotavirus
  • DTP
  • Polio
  • MMR
By Application
  • Hospital
  • Medical Center
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical advancements in admiration to the expansion of inactivated vaccines
      • 3.2.2. Rising infectious diseases and allergies
      • 3.2.3. Improving healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Longer timeline for vaccine production
      • 3.3.2. High cost associated with development of vaccine
    • 3.4. Market Trends
      • 3.4.1. Expansion of customised vaccines
      • 3.4.2. Implementation of Artificial Intelligence (AI) and Big Data Analytics to improve surveillance capacity
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Inactivated Vaccine, by Type, Application and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Inactivated Vaccine (Value)
      • 5.2.1. Global Inactivated Vaccine by: Type (Value)
        • 5.2.1.1. By End User
        • 5.2.1.2. Pediatrics
        • 5.2.1.3. Adults
        • 5.2.1.4. By Disease Indication
        • 5.2.1.5. Pneumococcal
        • 5.2.1.6. Influenza
        • 5.2.1.7. HPV
        • 5.2.1.8. Hepatitis
        • 5.2.1.9. Rotavirus
        • 5.2.1.10. DTP
        • 5.2.1.11. Polio
        • 5.2.1.12. MMR
      • 5.2.2. Global Inactivated Vaccine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Medical Center
      • 5.2.3. Global Inactivated Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Inactivated Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Limited (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MedImmune (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi Pasteur (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Serum Institute of India Pvt (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Inactivated Vaccine Sale, by Type, Application and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Inactivated Vaccine (Value)
      • 7.2.1. Global Inactivated Vaccine by: Type (Value)
        • 7.2.1.1. By End User
        • 7.2.1.2. Pediatrics
        • 7.2.1.3. Adults
        • 7.2.1.4. By Disease Indication
        • 7.2.1.5. Pneumococcal
        • 7.2.1.6. Influenza
        • 7.2.1.7. HPV
        • 7.2.1.8. Hepatitis
        • 7.2.1.9. Rotavirus
        • 7.2.1.10. DTP
        • 7.2.1.11. Polio
        • 7.2.1.12. MMR
      • 7.2.2. Global Inactivated Vaccine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Medical Center
      • 7.2.3. Global Inactivated Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Inactivated Vaccine: by Type(USD Million)
  • Table 2. Inactivated Vaccine By End User , by Region USD Million (2013-2018)
  • Table 3. Inactivated Vaccine Pediatrics , by Region USD Million (2013-2018)
  • Table 4. Inactivated Vaccine Adults , by Region USD Million (2013-2018)
  • Table 5. Inactivated Vaccine By Disease Indication , by Region USD Million (2013-2018)
  • Table 6. Inactivated Vaccine Pneumococcal , by Region USD Million (2013-2018)
  • Table 7. Inactivated Vaccine Influenza , by Region USD Million (2013-2018)
  • Table 8. Inactivated Vaccine HPV , by Region USD Million (2013-2018)
  • Table 9. Inactivated Vaccine Hepatitis , by Region USD Million (2013-2018)
  • Table 10. Inactivated Vaccine Rotavirus , by Region USD Million (2013-2018)
  • Table 11. Inactivated Vaccine DTP , by Region USD Million (2013-2018)
  • Table 12. Inactivated Vaccine Polio , by Region USD Million (2013-2018)
  • Table 13. Inactivated Vaccine MMR , by Region USD Million (2013-2018)
  • Table 14. Inactivated Vaccine: by Application(USD Million)
  • Table 15. Inactivated Vaccine Hospital , by Region USD Million (2013-2018)
  • Table 16. Inactivated Vaccine Medical Center , by Region USD Million (2013-2018)
  • Table 17. South America Inactivated Vaccine, by Country USD Million (2013-2018)
  • Table 18. South America Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 19. South America Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 20. Brazil Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 21. Brazil Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 22. Argentina Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 23. Argentina Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 24. Rest of South America Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 25. Rest of South America Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 26. Asia Pacific Inactivated Vaccine, by Country USD Million (2013-2018)
  • Table 27. Asia Pacific Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 28. Asia Pacific Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 29. China Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 30. China Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 31. Japan Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 32. Japan Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 33. India Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 34. India Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 35. South Korea Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 36. South Korea Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 37. Taiwan Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 38. Taiwan Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 39. Australia Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 40. Australia Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 41. Rest of Asia-Pacific Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 42. Rest of Asia-Pacific Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 43. Europe Inactivated Vaccine, by Country USD Million (2013-2018)
  • Table 44. Europe Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 45. Europe Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 46. Germany Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 47. Germany Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 48. France Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 49. France Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 50. Italy Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 51. Italy Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 52. United Kingdom Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 53. United Kingdom Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 54. Netherlands Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 55. Netherlands Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 56. Rest of Europe Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 57. Rest of Europe Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 58. MEA Inactivated Vaccine, by Country USD Million (2013-2018)
  • Table 59. MEA Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 60. MEA Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 61. Middle East Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 62. Middle East Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 63. Africa Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 64. Africa Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 65. North America Inactivated Vaccine, by Country USD Million (2013-2018)
  • Table 66. North America Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 67. North America Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 68. United States Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 69. United States Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 70. Canada Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 71. Canada Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 72. Mexico Inactivated Vaccine, by Type USD Million (2013-2018)
  • Table 73. Mexico Inactivated Vaccine, by Application USD Million (2013-2018)
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Inactivated Vaccine: by Type(USD Million)
  • Table 85. Inactivated Vaccine By End User , by Region USD Million (2019-2024)
  • Table 86. Inactivated Vaccine Pediatrics , by Region USD Million (2019-2024)
  • Table 87. Inactivated Vaccine Adults , by Region USD Million (2019-2024)
  • Table 88. Inactivated Vaccine By Disease Indication , by Region USD Million (2019-2024)
  • Table 89. Inactivated Vaccine Pneumococcal , by Region USD Million (2019-2024)
  • Table 90. Inactivated Vaccine Influenza , by Region USD Million (2019-2024)
  • Table 91. Inactivated Vaccine HPV , by Region USD Million (2019-2024)
  • Table 92. Inactivated Vaccine Hepatitis , by Region USD Million (2019-2024)
  • Table 93. Inactivated Vaccine Rotavirus , by Region USD Million (2019-2024)
  • Table 94. Inactivated Vaccine DTP , by Region USD Million (2019-2024)
  • Table 95. Inactivated Vaccine Polio , by Region USD Million (2019-2024)
  • Table 96. Inactivated Vaccine MMR , by Region USD Million (2019-2024)
  • Table 97. Inactivated Vaccine: by Application(USD Million)
  • Table 98. Inactivated Vaccine Hospital , by Region USD Million (2019-2024)
  • Table 99. Inactivated Vaccine Medical Center , by Region USD Million (2019-2024)
  • Table 100. South America Inactivated Vaccine, by Country USD Million (2019-2024)
  • Table 101. South America Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 102. South America Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 103. Brazil Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 104. Brazil Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 105. Argentina Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 106. Argentina Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 107. Rest of South America Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 108. Rest of South America Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 109. Asia Pacific Inactivated Vaccine, by Country USD Million (2019-2024)
  • Table 110. Asia Pacific Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 111. Asia Pacific Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 112. China Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 113. China Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 114. Japan Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 115. Japan Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 116. India Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 117. India Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 118. South Korea Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 119. South Korea Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 120. Taiwan Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 121. Taiwan Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 122. Australia Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 123. Australia Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 124. Rest of Asia-Pacific Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 125. Rest of Asia-Pacific Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 126. Europe Inactivated Vaccine, by Country USD Million (2019-2024)
  • Table 127. Europe Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 128. Europe Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 129. Germany Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 130. Germany Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 131. France Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 132. France Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 133. Italy Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 134. Italy Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 135. United Kingdom Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 136. United Kingdom Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 137. Netherlands Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 138. Netherlands Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 139. Rest of Europe Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 140. Rest of Europe Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 141. MEA Inactivated Vaccine, by Country USD Million (2019-2024)
  • Table 142. MEA Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 143. MEA Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 144. Middle East Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 145. Middle East Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 146. Africa Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 147. Africa Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 148. North America Inactivated Vaccine, by Country USD Million (2019-2024)
  • Table 149. North America Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 150. North America Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 151. United States Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 152. United States Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 153. Canada Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 154. Canada Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 155. Mexico Inactivated Vaccine, by Type USD Million (2019-2024)
  • Table 156. Mexico Inactivated Vaccine, by Application USD Million (2019-2024)
  • Table 157. Research Programs/Design for This Report
  • Table 158. Key Data Information from Secondary Sources
  • Table 159. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Inactivated Vaccine: by Type USD Million (2013-2018)
  • Figure 5. Global Inactivated Vaccine: by Application USD Million (2013-2018)
  • Figure 6. South America Inactivated Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 8. Europe Inactivated Vaccine Share (%), by Country
  • Figure 9. MEA Inactivated Vaccine Share (%), by Country
  • Figure 10. North America Inactivated Vaccine Share (%), by Country
  • Figure 11. Global Inactivated Vaccine share by Players 2018 (%)
  • Figure 12. Global Inactivated Vaccine share by Players (Top 3) 2018(%)
  • Figure 13. Global Inactivated Vaccine share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 16. Astellas Pharma (Japan) Revenue: by Geography 2018
  • Figure 17. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 18. CSL Limited (Australia) Revenue: by Geography 2018
  • Figure 19. Emergent BioSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 20. Emergent BioSolutions (United States) Revenue: by Geography 2018
  • Figure 21. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 23. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 25. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 26. MedImmune (United States) Revenue: by Geography 2018
  • Figure 27. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck & Co (United States) Revenue: by Geography 2018
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2018
  • Figure 31. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi Pasteur (France) Revenue: by Geography 2018
  • Figure 33. Serum Institute of India Pvt (India) Revenue, Net Income and Gross profit
  • Figure 34. Serum Institute of India Pvt (India) Revenue: by Geography 2018
  • Figure 35. Global Inactivated Vaccine: by Type USD Million (2013-2018)
  • Figure 36. Global Inactivated Vaccine: by Application USD Million (2013-2018)
  • Figure 37. South America Inactivated Vaccine Share (%), by Country
  • Figure 38. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 39. Europe Inactivated Vaccine Share (%), by Country
  • Figure 40. MEA Inactivated Vaccine Share (%), by Country
  • Figure 41. North America Inactivated Vaccine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Astellas Pharma (Japan)
  • CSL Limited (Australia)
  • Emergent BioSolutions (United States)
  • GlaxoSmithKline (United Kingdom)
  • Johnson & Johnson (United States)
  • MedImmune (United States)
  • Merck & Co (United States)
  • Pfizer (United States)
  • Sanofi Pasteur (France)
  • Serum Institute of India Pvt (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation